CRISPR Therapeutics (CRSP) vs Immunovant (IMVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunovant (IMVT) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 98.9% versus a loss of 25.9%. Over five years, IMVT leads with a +267.4% price change compared with -46.0% for CRSP. Immunovant is the larger company by market cap ($6.31 billion vs $4.87 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRSP | IMVT |
|---|---|---|
| Share price | $50.36 | $30.56 |
| Market cap | $4.87B | $6.31B |
| 1-day change | -3.80% | -4.62% |
| YTD return | -0.17% | +26.04% |
| 1-year return | -25.87% | +98.88% |
| 5-year return | -46.03% | +267.43% |
| EPS (TTM) | $-4.74 | $-2.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.51M | — |
| Revenue growth (YoY) | -90.59% | — |
| Net income (latest FY) | $-581.60M | $-505.61M |
| Operating margin | -18933.65% | — |
| Net margin | -16569.77% | — |
| 52-week high | $78.38 | $45.42 |
| 52-week low | $44.12 | $16.08 |
| Distance from 52-week high | -35.75% | -32.72% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +73.87% | +59.95% |
| Average volume | 1.59M | 1.22M |
| Shares outstanding | 96.69M | 206.55M |
| Employees | — | 315 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMVT has outperformed CRSP by 124.8 percentage points over the past year.
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
CRSP vs IMVT FAQ
Which is bigger, CRISPR Therapeutics or Immunovant?
Immunovant (IMVT) is larger, with a market capitalization of $6.31B compared with $4.87B for CRISPR Therapeutics (CRSP).
Which stock has performed better over the past year, CRSP or IMVT?
IMVT returned +98.88% over the past 12 months, compared with -25.87% for CRSP (price return, excluding dividends). Past performance does not predict future results.
Are CRISPR Therapeutics and Immunovant in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.